CA-NEXTIVITY
Nextivity today announced that Nordic distributor Tura Scandinavia AB has the first European installation of Cel-Fi QUATRA 4000e underway. The new multi-carrier hybrid active DAS (distributed antenna system) for the EMEA market has been deployed at Elgiganten and Rusta stores in northern Stockholm, Sweden so customers and employees can now use their cell phones anywhere inside the stores, and experience good quality reception.
Spotty cellular coverage, poor voice quality, dropped calls, and dead zones continue to impact employees and customers in many retail buildings. Cel-Fi QUATRA 4000e is an affordable, all-digital, multi-carrier active DAS hybrid solution that solves this issue by providing uniform, high quality cellular signal throughout any commercial building. This industry-leading system is also carrier approved and guaranteed network safe.
“There was no cellular reception at all inside the Elgiganten and Rusta stores due to the metal construction of the buildings, which is common for commercial property in Sweden,” says Terje Skatterod, Senior Technology Officer at Tura Scandinavia, a Nordic distributor that offers mobile, data, and cellular equipment for retailers through a network of system integrators. “Cel-Fi QUATRA has improved the signal inside the stores by 25 dBM, which is equivalent to increasing the coverage by almost 100 times.”
“As Cel-Fi QUATRA is 5G-ready, building owners get a greater return on their investment with this modern solution which is upgradable,” explains Sverre Platou, Nextivity Brand Manager at Tura Scandinavia. “The system is also all-digital, using ethernet rather than coax cabling, which makes installation easier and reduces the installation cost to about a quarter of traditional repeater systems.”
“Cel-Fi QUATRA is starting to get a lot of attention in the Nordic region. Unlike other equipment, you don't need the RF skills to install it. You can simply use a local electrician to run the cabling and hook it up to the internet, and one telecom RF engineer to deploy the whole solution remotely,” Skatterod says.
Tura Scandinavia, which was named best European distributor in 2021 by Nextivity, has several installations of the new Cel-Fi QUATRA 4000e scheduled for other retailers in Sweden and throughout Europe. For more information about QUATRA, visit cel-fi.com/buy .
“Tura Scandinavia is a strong strategic partner for Nextivity, bringing our best-in-class cellular coverage solutions to the reseller community,” says David Cabanes, Nextivity Vice-President of European Sales. “With product offerings now available for enterprise, small and mid-size businesses, mobile, and micro solutions, we look forward to continuing to work with Tura Scandinavia to help their partners expand their capabilities and market reach.”
About Tura Scandinavia AB
Tura Scandinavia AB is a leading Nordic distributor of accessories in Audio, Video, Mobile, Data, Photography, TV, Gaming and SDA. Our philosophy is: a wide range, strong brands and fast delivery. The business was founded in Gothenburg in 1976 and we currently operate in Sweden, Denmark, Finland and Norway. The head office is located in Kungsbacka and the logistics center in Nässjö, Sweden.
About Nextivity
Headquartered in San Diego, Nextivity Inc. develops the award-winning, Cel-Fi family of products that deliver best-in-class connectivity for enterprise, business, residential spaces, and mobile cellular and public safety communication needs. Cel-Fi is the go-to solution for healthcare, government, hotels, retail, education, remote sites, parking garages, manufacturing, warehouses, as well as trucking and marine fleets. Cel-Fi products are available in 100 countries through mobile operators and a growing worldwide network of master distributors, systems integrators, installers, and resellers. Additional information is available at cel-fi.com , on Twitter , LinkedIn , and on Facebook .
Nextivity, the Nextivity logo, Cel-Fi, Smart Signal Booster, and Supercell are registered trademarks of Nextivity Incorporated in the United States and/or other countries. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220314005864/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom